Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 31 July 2012 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) has released a new draft guideline for sponsors of human normal immunoglobulin for subcutaneous and/or intramuscular administration pertaining to the summary of product characteristics (SmPC) required to be submitted to EMA and the European Commission.
The guideline, released 31 July 2012 by EU regulators, notes sponsors of the products will be required to list different SmPCs on the product depending on whether it is intended for subcutaneous administration, intramuscular administration or both.
While several aspects of the harmonized SmPC labeling standard are product-specific-its effect on pediatric populations, excipients used, contraindications, safety issues and preclinical safety data, for example-it presents a largely similar template capable of being used by most immunoglobulin products.
EMA regulators said the guideline will eventually replace an earlier 2002 guideline of a similar name.
EMA - Draft guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration
Tags: Immunoglobulin, SmPC, Draft Guideline, Latest News